Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

被引：0

作者：

Huang, Si-Man ^{[1
,2
,3
]}

Wan, Chao-Ling ^{[1
,2
,3
]}

Cao, Han-Yu ^{[1
,2
,3
]}

Li, Yan-Yan ^{[1
,2
,3
]}

Qian, Chong-Sheng ^{[1
,2
,3
]}

Zhou, Hai-Xia ^{[1
,2
,3
]}

Xu, Ming-Zhu ^{[1
,2
,3
]}

Hu, Xiao-Hui ^{[1
,2
,3
]}

Dai, Lan ^{[1
,2
,3
]}

Dai, Hai-Ping ^{[1
,2
,3
]}

Xue, Sheng-Li ^{[1
,2
,3
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, 188 Shizi St, Suzhou 215006, Peoples R China

[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

[3] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China

来源：

CLINICAL CASE REPORTS | 2023年 / 11卷 / 12期

关键词：

B-ALL; CD22; inotuzumab ozogamicin; MRD positive; relapsed and refractory; ADULTS;

D O I：

10.1002/ccr3.8289

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

引用

页数：5

共 50 条

[1] Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
Wullenkord, Ramona
Reicherts, Christian
Mikesch, Jan-Henrik
Marx, Julia
Wethmar, Klaus
Albring, Joern
Call, Simon
Lenz, Georg
Stelljes, Matthias
ANNALS OF HEMATOLOGY, 2021, 100 (02) : 587 - 589
[2] Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
Ramona Wullenkord
Christian Reicherts
Jan-Henrik Mikesch
Julia Marx
Klaus Wethmar
Jörn Albring
Simon Call
Georg Lenz
Matthias Stelljes
Annals of Hematology, 2021, 100 : 587 - 589
[3] Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
Jabbour, Elias
Haddad, Fadi G.
Short, Nicholas J.
Senapati, Jayastu
Jain, Nitin
Sasaki, Koji
Jorgensen, Jeffrey
Wang, Sa A.
Alvarado, Yesid
Wang, Xuemei
Dinardo, Courtney
Masarova, Lucia
Kadia, Tapan
Garris, Rebecca S.
Ravandi, Farhad
Kantarjian, Hagop
BLOOD, 2024, 143 (05) : 417 - 421
[4] A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia
Short, Nicholas J.
Kantarjian, Hagop
Alvarado, Yesid
Burger, Jan A.
Jain, Nitin
Konopleva, Marina
Ravandi, Farhad
DiNardo, Courtney D.
Masarova, Lucia
Sasaki, Koji
Thompson, Philip A.
Ferrajoli, Alessandra
Jacob, Jovitta
Milton, Anna
Garris, Rebecca
Jabbour, Elias J.
BLOOD, 2021, 138
[5] Development of Inotuzumab Ozogamicin and Blinatumomab for Frontline Treatment of Older Patients with Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Wieduwilt, Matthew
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S31 - S33
[6] A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
Senapati, Jayastu
Short, Nicholas
Alvarado, Yesid
Burger, Jan A.
Jain, Nitin
Konopleva, Marina
Ravandi, Farhad
DiNardo, Courtney D.
Masarova, Lucia
Sasaki, Koji
Thompson, Philip A.
Ferrajoli, Alessandra
Jacob, Jovitta
Mayor, Ejiroghene
Milton, Anna
Loiselle, Christopher
Garris, Rebecca
Kantarjian, Hagop
Jabbour, Elias
BLOOD, 2022, 140 : 3253 - 3255
[7] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
Yang, Tingting
Dong, Yetian
Zhang, Mingming
Feng, Jingjing
Fu, Shan
Xiao, Pingnan
Hong, Ruimin
Xu, Huijun
Cui, Jiazhen
Huang, Simao
Wei, Guoqing
Chang, Alex H.
Huang, He
Hu, Yongxian
BLOOD, 2024, 144 : 2819 - 2819
[8] Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Goekbuget, Nicola
Dombret, Nerve
Giebel, Sebastian
Bruggemann, Monika
Doubek, Michael
Foa, Robin
Hoelzer, Dieter
Kim, Christopher
Martinelli, Giovanni
Parovichnikova, Elena
Rambaldi, Alessandro
Ribera, Josep-Maria
Schoonen, Marieke
Stieglmaier, Julia M.
Zugmaier, Gerhard
Bassan, Renato
HEMATOLOGY, 2019, 24 (01) : 337 - 348
[9] Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia
Nagafuji, Koji
Miyamoto, Toshihiro
Eto, Tetsuya
Ogawa, Ryosuke
Okumura, Hirokazu
Takase, Ken
Kawano, Noriaki
Miyazaki, Yasuhiko
Fujisaki, Tomoaki
Wake, Atsushi
Ohno, Yuju
Kurokawa, Toshiro
Kamimura, Tomohiko
Takamatsu, Yasushi
Yokota, Shouhei
Akashi, Koichi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 164 - 171
[10] Allogeneic CD19-CART Therapy to the Rescue of a Pediatric Patient with Relapsed and Refractory Acute B Lymphoblastic Leukemia
Chang, Lung-Ji
Zhang, Jian-Ping
Liu, Yu-Chen
Dong, Lujia
Wu, Tong
Lu, Dao-Pei
MOLECULAR THERAPY, 2016, 24 : S76 - S76

← 1 2 3 4 5 →